• Twitter
  • Jobs
ProCURE oncology
  • HOME
  • ABOUT US
  • RESEARCH GROUP
    • Molleví’s Lab
    • Antolin’s Lab
    • Alemany’s & Piulats’s lab
    • Martínez-Balibrea’s Lab
    • Aytes’s Lab
    • Belver’s Lab
    • Pujana’s Lab
    • Menendez’s Lab
    • Sureda’s & Farre’s Lab
    • Casanovas’s Lab
    • Viñals’s lab
  • INNOVATION
  • NEWS
  • CONTACT
  • Menu Menu
VIEW ALL RESEARCH-GROUP

Tumor angiogenesis group
Casanovas’ Lab

DESCRIPTION

Mechanisms of resistance to antiangiogenic therapies.
Therapeutic studies in Kidney Cancer murine models, both PDOX and syngenic.
Therapeutic studies in pancreatic NeuroEndocrine tumors.
Discovery of non-invasive biomarkers in clinical trials with antiangiogenics.

Our research group at the ProCURE Program (Catalan Institute of Oncology) and OncoBell Program (IDIBELL) is focused on determining the consequences of adaptation and resistance to anti-angiogenic cancer therapy. For that we use translational research in murine models of cancer, particularly Kindey Cancer PDOX models and NeuroEndocrine transgenic models to study in vivo mechanisms of adaptation to anti-angiogenics, and validate our findings using clinical samples from our hospital and collaborating institutions.
Our scientific achievements have been published in prestigious journals in the field of cancer research with numerous “preview”, “highlight” or commentary articles in high impact scientific journals. Furthermore, we have an important international position in the field of antitumor therapies and angiogenic resistance mechanisms.

Group members

Felix-Joan Peix

Young investigators

Laura Puigròs

Young investigators

Jessica Videira

Young investigators

Maria Del Mar Martinez Lozano

Support staff

Irene Ortiz-Rubio

Researchers

Laura Bernaus

Support staff

Publications

The adaptive stroma joining the antiangiogenic resistance front

26 de March de 2011/in Casanovas's Lab/by miguel

J Clin Invest. 2011 Apr;121(4):1244-7. doi: 10.1172/JCI46430. Epub 2011 Mar 23. ABSTRACT Resistance to antiangiogenic therapies in cancer involves both tumor cells and stromal components, but their relative contributions differ in each cancer subtype. In this issue of the JCI, Cascone et al. describe a stromal adaptation to antiangiogenic therapy in non-small cell lung carcinoma […]

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2011-03-26 10:00:002011-03-26 10:00:00The adaptive stroma joining the antiangiogenic resistance front

Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing

4 de March de 2011/in Casanovas's Lab/by miguel

Proc Natl Acad Sci U S A. 2011 Mar 15;108(11):4394-9. doi: 10.1073/pnas.1014720108. Epub 2011 Feb 28. ABSTRACT MicroRNAs (miRNAs) are small RNA molecules that regulate gene expression at the posttranscriptional level and are critical for many cellular pathways. The disruption of miRNAs and their processing machineries also contributes to the development of human tumors. A […]

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2011-03-04 11:00:002011-03-04 11:00:00Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing

The use of caspase inhibitors in pulsed-field gel electrophoresis may improve the estimation of radiation-induced DNA repair and apoptosis

18 de January de 2011/in Casanovas's Lab/by miguel

Radiat Oncol. 2011 Jan 15;6:6. doi: 10.1186/1748-717X-6-6. ABSTRACT BACKGROUND: Radiation-induced DNA double-strand break (DSB) repair can be tested by using pulsed-field gel electrophoresis (PFGE) in agarose-encapsulated cells. However, previous studies have reported that this assay is impaired by the spontaneous DNA breakage in this medium. We investigated the mechanisms of this fragmentation with the principal […]

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2011-01-18 11:00:002011-01-18 11:00:00The use of caspase inhibitors in pulsed-field gel electrophoresis may improve the estimation of radiation-induced DNA repair and apoptosis

Filamin B plays a key role in vascular endothelial growth factor-induced endothelial cell motility through its interaction with Rac-1 and Vav-2

30 de January de 2010/in Casanovas's Lab/by miguel

J Biol Chem. 2010 Apr 2;285(14):10748-60. doi: 10.1074/jbc.M109.062984. Epub 2010 Jan 28. ABSTRACT Actin-binding proteins filamin A (FLNA) and B (FLNB) are expressed in endothelial cells and play an essential role during vascular development. In order to investigate their role in adult endothelial cell function, we initially confirmed their expression pattern in different adult mouse […]

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2010-01-30 11:00:002010-01-30 11:00:00Filamin B plays a key role in vascular endothelial growth factor-induced endothelial cell motility through its interaction with Rac-1 and Vav-2

Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors

7 de May de 2009/in Casanovas's Lab/by miguel

Clin Cancer Res. 2009 May 15;15(10):3384-95. doi: 10.1158/1078-0432.CCR-08-2170. Epub 2009 May 5. ABSTRACT PURPOSE: Germ cell tumors (GCT) of the testis are highly curable, but those patients who are refractory to cisplatin (CDDP)-based combination chemotherapy have a poor prognosis. Therefore, identifying new alternatives for treatment remains a priority. Several studies support an important role for […]

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2009-05-07 10:00:002009-05-07 10:00:00Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors
Page 13 of 16«‹1112131415›»

Research Projects

  1. MICIU PID2022-142386OB-I00 Disección de los mecanismos de Plaquetas y genes de Coagulación en la metástasis del Cancer de Riñón Oriol Casanovas 325.000,00 €PREP2022-000672 Disección de los mecanismos de Plaquetas y genes de Coagulación en la metástasis del Cancer de Riñón Oriol Casanovas 111.758,00 €
    Proyecto PID2022-142386OB-I00 financiado por MCIU/AEI/10.13039/501100011033 y por FEDER, UE
  2. MTV3 201910-30 Identification of Kidney Cancer progression targets and biomarkers through CRISPRengineered organoids and xenograft mouse models Oriol Casanovas 136.250,00 €
  3. MICIU PID2019-107557RB-I00 Targeteando la Coagulación en la formación de metástasis en cáncer renal Oriol Casanovas 145.200,00 €
    Proyecto PID2019-107557RB-I00 financiado por MICIU/AEI /10.13039/501100011033
  4. AGAUR 2021 SGR 01289 Interacció Tumor Estroma i Resistència Terapèutica – ITERT Oriol Casanovas 40.000,00 €

    Tech Transfer Projects

  5. MICIU CPP2023-010718 Opening a New Era in Hepatocellular Carcinoma by a Novel Blood Biomarker for Individual Selection of Treatment (PersonalHCC) Oriol Casanovas 514.874,00 €
    Proyecto CPP2023-010718 financiado por MICIU/AEI/10.13039/501100011033 y por FEDER, UE.
  6. AGAUR 2022 DI 00052 Inhibiting Cannibalism to Fight Resistant Tumors Oriol Casanovas 33.960,00 €
  7. MICIU PDC2021-121308-I00 Desarrollo de un nuevo biomarcador y su ‘kit’ prototipo para predecir la Respuesta Agresiva en Cancer Oriol Casanovas 132.250,00 €
    Proyecto PDC2021-121308-I00 financiado por MCIU/AEI/10.13039/501100011033 y por la Unión Europea NextGenerationEU/ PRTR
  8. ISCIII DTS21/00163 Angiotheragnostics: Desarrollo de un nuevo tratamiento con su biomarcador de selección de pacientes para pacientes con cáncer colorectal avanzado. Oriol Casanovas 149.600,00 €


Collaborations

International:
Douglas Hanahan, ISREC

Gabriele Bergers, KULeuven

Masahiro Inoue, Univ.Osaka

Kristian Pietras, Karolinska I.

Enrico Giraudo, IRCC

Stefano Indraccolo, IOV


National:

Joan Carles, VHIO

Cristina Suárez, VHIO

Maria Ochoa, ICO

August Vidal, HUB

Ramon Salazar, ICO

X García del Muro, ICO

Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

© Copyright - Edisenius
  • Privacy Policy
  • Cookie Policy
  • Legal Notice
Sureda’s & Farre’s LabGrup-Hematoligia-webViñals's labViñals’s lab
Scroll to top
Manage cookie consent
To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.
Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Storage or technical access that is used exclusively for anonymous statistical purposes. Without a requirement, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles to send advertising, or to track the user on a website or several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}